Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta‐analysis
Abstract Introduction The question remains to be elucidated: “Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?” It is crucial to confirm this in order to provide appropriate treatments for Japanese patients with major depressive disorder (MDD). T...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | Neuropsychopharmacology Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/npr2.12376 |
| _version_ | 1797263674507788288 |
|---|---|
| author | Taro Kishi Kenji Sakuma Masakazu Hatano Yuki Matsuda Satoru Esumi Nobumi Miyake Itaru Miura Hikaru Hori Masaki Kato Nakao Iwata |
| author_facet | Taro Kishi Kenji Sakuma Masakazu Hatano Yuki Matsuda Satoru Esumi Nobumi Miyake Itaru Miura Hikaru Hori Masaki Kato Nakao Iwata |
| author_sort | Taro Kishi |
| collection | DOAJ |
| description | Abstract Introduction The question remains to be elucidated: “Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?” It is crucial to confirm this in order to provide appropriate treatments for Japanese patients with major depressive disorder (MDD). Therefore, we conducted a systematic review and random‐effects pairwise meta‐analysis including these nine double‐blind, randomized, placebo‐controlled trials. Methods We calculated the standardized mean difference (SMD) and risk ratio (RR) with a 95% confidence interval (95% CI). Results Pooled newer antidepressants outperformed placebo regarding improvement of depressive symptom scale scores [SMD (95% CI) = −0.20 (−0.27, −0.12), p < 0.00001], response to treatment [RR (95% CI) = 1.23 (1.13, 1.32), p < 0.00001], and remission rate [RR (95% CI) = 1.30 (1.16, 1.45), p < 0.00001]. Although all‐cause discontinuation was not significantly different between the treatment groups, the pooled antidepressant group showed a higher discontinuation rate due to adverse event [RR (95% CI) = 1.60 (1.13, 2.26), p = 0.007] and a higher incidence of at least one adverse event than the placebo group [RR (95% CI) = 1.13 (1.08, 1.18), p < 0.00001]. Discussion We concluded that newer antidepressants are effective for Japanese adults with MDD although the clinicians must monitor the health conditions of these individuals. |
| first_indexed | 2024-04-25T00:16:46Z |
| format | Article |
| id | doaj.art-7bd9cab4e4ec4052919a8dd7b78746e1 |
| institution | Directory Open Access Journal |
| issn | 2574-173X |
| language | English |
| last_indexed | 2024-04-25T00:16:46Z |
| publishDate | 2024-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neuropsychopharmacology Reports |
| spelling | doaj.art-7bd9cab4e4ec4052919a8dd7b78746e12024-03-13T03:12:13ZengWileyNeuropsychopharmacology Reports2574-173X2024-03-0144121622010.1002/npr2.12376Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta‐analysisTaro Kishi0Kenji Sakuma1Masakazu Hatano2Yuki Matsuda3Satoru Esumi4Nobumi Miyake5Itaru Miura6Hikaru Hori7Masaki Kato8Nakao Iwata9Department of Psychiatry Fujita Health University School of Medicine Toyoake Aichi JapanDepartment of Psychiatry Fujita Health University School of Medicine Toyoake Aichi JapanDepartment of Pharmacotherapeutics and Informatics Fujita Health University School of Medicine Toyoake Aichi JapanDepartment of Psychiatry Jikei University School of Medicine, Minato Tokyo JapanFaculty of Pharmaceutical Sciences Kobe Gakuin University Kobe Hyogo JapanDepartment of Neuropsychiatry St. Marianna University School of Medicine Kawasaki Kanagawa JapanDepartment of Neuropsychiatry Fukushima Medical University School of Medicine Fukushima JapanDepartment of Psychiatry, Faculty of Medicine Fukuoka University Fukuoka JapanDepartment of Neuropsychiatry Kansai Medical University Osaka JapanDepartment of Psychiatry Fujita Health University School of Medicine Toyoake Aichi JapanAbstract Introduction The question remains to be elucidated: “Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?” It is crucial to confirm this in order to provide appropriate treatments for Japanese patients with major depressive disorder (MDD). Therefore, we conducted a systematic review and random‐effects pairwise meta‐analysis including these nine double‐blind, randomized, placebo‐controlled trials. Methods We calculated the standardized mean difference (SMD) and risk ratio (RR) with a 95% confidence interval (95% CI). Results Pooled newer antidepressants outperformed placebo regarding improvement of depressive symptom scale scores [SMD (95% CI) = −0.20 (−0.27, −0.12), p < 0.00001], response to treatment [RR (95% CI) = 1.23 (1.13, 1.32), p < 0.00001], and remission rate [RR (95% CI) = 1.30 (1.16, 1.45), p < 0.00001]. Although all‐cause discontinuation was not significantly different between the treatment groups, the pooled antidepressant group showed a higher discontinuation rate due to adverse event [RR (95% CI) = 1.60 (1.13, 2.26), p = 0.007] and a higher incidence of at least one adverse event than the placebo group [RR (95% CI) = 1.13 (1.08, 1.18), p < 0.00001]. Discussion We concluded that newer antidepressants are effective for Japanese adults with MDD although the clinicians must monitor the health conditions of these individuals.https://doi.org/10.1002/npr2.12376efficacyJapanese major depressive disordernewer antidepressantsafetysystematic review and meta‐analysis |
| spellingShingle | Taro Kishi Kenji Sakuma Masakazu Hatano Yuki Matsuda Satoru Esumi Nobumi Miyake Itaru Miura Hikaru Hori Masaki Kato Nakao Iwata Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta‐analysis Neuropsychopharmacology Reports efficacy Japanese major depressive disorder newer antidepressant safety systematic review and meta‐analysis |
| title | Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta‐analysis |
| title_full | Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta‐analysis |
| title_fullStr | Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta‐analysis |
| title_full_unstemmed | Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta‐analysis |
| title_short | Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta‐analysis |
| title_sort | newer antidepressant for japanese adults with major depressive disorder a systematic review and meta analysis |
| topic | efficacy Japanese major depressive disorder newer antidepressant safety systematic review and meta‐analysis |
| url | https://doi.org/10.1002/npr2.12376 |
| work_keys_str_mv | AT tarokishi newerantidepressantforjapaneseadultswithmajordepressivedisorderasystematicreviewandmetaanalysis AT kenjisakuma newerantidepressantforjapaneseadultswithmajordepressivedisorderasystematicreviewandmetaanalysis AT masakazuhatano newerantidepressantforjapaneseadultswithmajordepressivedisorderasystematicreviewandmetaanalysis AT yukimatsuda newerantidepressantforjapaneseadultswithmajordepressivedisorderasystematicreviewandmetaanalysis AT satoruesumi newerantidepressantforjapaneseadultswithmajordepressivedisorderasystematicreviewandmetaanalysis AT nobumimiyake newerantidepressantforjapaneseadultswithmajordepressivedisorderasystematicreviewandmetaanalysis AT itarumiura newerantidepressantforjapaneseadultswithmajordepressivedisorderasystematicreviewandmetaanalysis AT hikaruhori newerantidepressantforjapaneseadultswithmajordepressivedisorderasystematicreviewandmetaanalysis AT masakikato newerantidepressantforjapaneseadultswithmajordepressivedisorderasystematicreviewandmetaanalysis AT nakaoiwata newerantidepressantforjapaneseadultswithmajordepressivedisorderasystematicreviewandmetaanalysis |